Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022
- PMID: 35239637
- PMCID: PMC8893335
- DOI: 10.15585/mmwr.mm7109e2
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022
Abstract
As of February 20, 2022, only BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine has been authorized for use in persons aged 12-17 years in the United States (1). The Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech vaccine on December 9, 2021, to authorize a homologous* booster dose for persons aged 16-17 years ≥6 months after receipt of dose 2 (1). On January 3, 2022, authorization was expanded to include persons aged 12-15 years, and for all persons aged ≥12 years, the interval between dose 2 and booster dose was shortened to ≥5 months (1). To characterize the safety of Pfizer-BioNTech booster doses among persons aged 12-17 years (adolescents), CDC reviewed adverse events and health impact assessments during the week after receipt of a homologous Pfizer-BioNTech booster dose reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA. During December 9, 2021-February 20, 2022, approximately 2.8 million U.S. adolescents received a Pfizer-BioNTech booster dose.† During this period, receipt of 3,418 Pfizer-BioNTech booster doses were reported to v-safe for adolescents. Reactions were reported to v-safe with equal or slightly higher frequency after receipt of a booster dose than after dose 2, were primarily mild to moderate in severity, and were most frequently reported the day after vaccination. VAERS received 914 reports of adverse events after Pfizer-BioNTech booster dose vaccination of adolescents; 837 (91.6%) were nonserious and 77 (8.4%) were serious. Health care providers, parents, and adolescents should be advised that local and systemic reactions are expected among adolescents after homologous Pfizer-BioNTech booster vaccination, and that serious adverse events are rare.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Figures
![FIGURE](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8893335/bin/mm7109e2-F.gif)
Similar articles
-
Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.Vaccine. 2024 Apr 2;42(9):2380-2384. doi: 10.1016/j.vaccine.2024.02.084. Epub 2024 Mar 11. Vaccine. 2024. PMID: 38462432 Review.
-
COVID-19 Vaccine Safety First Year Findings in Adolescents.Pediatrics. 2023 May 1;151(5):e2022060295. doi: 10.1542/peds.2022-060295. Pediatrics. 2023. PMID: 37082919 Free PMC article. Review.
-
Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.MMWR Morb Mortal Wkly Rep. 2022 Aug 19;71(33):1047-1051. doi: 10.15585/mmwr.mm7133a3. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35980875 Free PMC article.
-
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249-254. doi: 10.15585/mmwr.mm7107e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35176008 Free PMC article.
-
COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1053-1058. doi: 10.15585/mmwr.mm7031e1. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34351881 Free PMC article.
Cited by
-
Anxiety Levels among Healthcare Workers during the COVID-19 Pandemic and Attitudes towards COVID-19 Vaccines.Vaccines (Basel). 2024 Mar 28;12(4):366. doi: 10.3390/vaccines12040366. Vaccines (Basel). 2024. PMID: 38675748 Free PMC article.
-
Association Between the "We Can Do This" Campaign and COVID-19 Booster Uptake, U.S., 2021-2022.AJPM Focus. 2024 Jan 4;3(2):100183. doi: 10.1016/j.focus.2024.100183. eCollection 2024 Apr. AJPM Focus. 2024. PMID: 38357552 Free PMC article.
-
Association Between Pfizer COVID-19 Vaccine Adverse Effects and Diabetes Mellitus: A Prospective Multicenter Study.Cureus. 2023 Nov 4;15(11):e48263. doi: 10.7759/cureus.48263. eCollection 2023 Nov. Cureus. 2023. PMID: 38054118 Free PMC article.
-
A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations.J Infect Dis. 2023 Aug 4;228(Suppl 1):S70-S76. doi: 10.1093/infdis/jiad150. J Infect Dis. 2023. PMID: 37539763 Free PMC article.
-
Common Side Effects of Pfizer COVID-19 Vaccine: An Experience From Pakistan.Cureus. 2023 Jun 23;15(6):e40878. doi: 10.7759/cureus.40878. eCollection 2023 Jun. Cureus. 2023. PMID: 37492805 Free PMC article.
References
-
- Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine letter of authorization. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/150386/download
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials